Table 1.
Antibacterial treatments received within 72 h prior to starting study treatment in ASPECT-NP participantsa who were failing prior antibacterial therapy
| Antibacterial treatment, n (%) | C/T (N = 53) | MEM (N = 40) |
|---|---|---|
| Piperacillin/tazobactam | 16 (30.2) | 17 (42.5) |
| Fluoroquinolones | 15 (28.3) | 12 (30.0) |
| Third/fourth-generation cephalosporins | 13 (24.5) | 16 (40.0) |
| Cefepime | 4 (7.5) | 3 (7.5) |
| Cefotaxime | 0 | 4 (10.0) |
| Ceftriaxone | 9 (17.0) | 6 (15.0) |
| Amoxicillin/clavulanate | 6 (11.3) | 2 (5.0) |
| Ampicillin/sulbactam | 5 (9.4) | 1 (2.5) |
| Aminoglycosides | 7 (13.2) | 4 (10.0) |
| Amikacin | 5 (9.4) | 4 (10.0) |
| Macrolides | 3 (5.7) | 1 (2.5) |
| Carbapenems | 2 (3.8) | 3 (7.5) |
| Cefoperazone/sulbactam | 4 (7.5) | 3 (7.5) |
Includes all systemic antibacterial treatments with potential gram-negative activity administered within 72 h prior to starting study treatment; participants may have received multiple treatments sequentially and/or concomitantly
C/T Ceftolozane/tazobactam, MEM Meropenem, vHABP Ventilated hospital-acquired bacterial pneumonia, VABP Ventilator-associated bacterial pneumonia
aIn ≥ 3 participants